CGON vs MRNA
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Oct 22, 2026
CGON
MRNA
Investment Advisor Scores
MRNA
Oct 22, 2026AI Analyst Insights
Detailed Metrics Comparison
| Metric | CGON | MRNA | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 0 | 23.0415 | Tie |
| PEG Ratio | 0 | 0 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 1982.7% | 2.1% | CGON |
| Earnings Growth | 0.0% | -85.1% | CGON |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 73.4/100 | 35.1/100 | CGON |
| Profit Margin | 0.0% | -141.4% | CGON |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
| Implied Volatility | N/A | N/A | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | STRONG BUY | EXTENDED | CGON |
Relative Price Performance (Last 90 Days)
Current Technical Phase
CGON
MarkdownPrice below a falling SMA50 (slope -3.9%), weak momentum, RSI 38
MRNA
MarkupPrice above SMA50, rising 50-day trend (58.0% over 20 days), RSI 69
Fundamentals Snapshot
| Metric | CGON | MRNA |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | -20.6 | -51.1 |
| Trailing P/E | — | — |
| Revenue (TTM) | — | — |
| Revenue Growth | 19.8% | 0.0% |
| Gross Margin | -25.9% | -0.7% |
| Operating Margin | -74.7% | -5.6% |
| EPS | -2.69 | -7.98 |
| Dividend Yield | — | — |